On August 3, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) released its annual report. Highlights from 2022-2023 include:
- Development of procedures for review of nationally procured pharmaceuticals and delivery of implementation advice for certain COVID-19 treatments.
- Reports on evidence and resources for post-COVID condition (also known as long COVID).
- Creation of new reimbursement review pathways including the Non-Sponsored Single Drug Review and Streamlined Drug Class Review and a consultation on time-limited drug reimbursement recommendations.
- Creation of the Post-Market Drug Evaluation Program.
- Release of the 2023 Watch List: Top 10 Precision Medicine Technologies and Issues.
- Start of a learning period and development of draft guidance regarding the use of real-world evidence.
- Report on a potential pan-Canadian formulary.
Related Publications & Articles
-
CDA opens consultation on proposed list of drugs to inform development of national formulary
On June 19, 2025, Canada’s Drug Agency (CDA) opened a public consultation on a proposed process for preparing a list of essential prescription drugs and related products.Read More -
Finalized PMPRB Guidelines published
On June 30, 2025, the Patented Medicine Prices Review Board (PMPRB) published its new Guidelines for PMPRB Staff, which will come into force on January 1, 2026.Read More -
2025 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories.Read More